- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04867707
Role of Neuraminidase Activity on Endothelial Dysfunction in Type 2 Diabetes (NAED)
July 3, 2023 updated by: Luis Martinez-Lemus, DVM, PhD, University of Missouri-Columbia
The objective is to determine if neuraminidase inhibition with zanamivir is efficacious as a therapeutic strategy to restore endothelial function in T2D patients.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
Twenty subjects will complete five days of treatment with zanamivir.
Baseline measurements will be taken before the initiation of treatment, as well as after the conclusion of the treatment period (i.e., a total of two assessment visits per subject).
Assessment visits will include: vitals (such as blood pressure, heart rate), fasting blood work for plasma neuraminidase activity, plasma sialic acid, plasma glucose and plasma insulin, brachial artery FMD, and glycocalyx integrity assessment via Glycocheck.
Study Type
Interventional
Enrollment (Actual)
14
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Luis Martinez-Lemus, PhD
- Phone Number: (573) 882-3244
- Email: martinezlemusl@missouri.edu
Study Contact Backup
- Name: Jaume Padilla, PhD
- Phone Number: (573) 882-7056
- Email: padillaja@missouri.edu
Study Locations
-
-
Missouri
-
Columbia, Missouri, United States, 65212
- University of Missouri, School of Medicine Clinical Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
45 years to 64 years (Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Men and women with a BMI of 25-39 kg/m2
- Ages 45-64 years at randomization.
- Diagnosis of T2D classified based on physician diagnosis.
- No vulnerable populations (e.g., prisoners, pregnant, children) will be enrolled.
Exclusion Criteria:
- Cardiovascular disease including myocardial infraction, heart failure, coronary artery disease, stroke
- History of chronic renal or hepatic disease
- Active cancer
- Autoimmune diseases
- Immunosuppressant therapy
- Hormone replacement therapy
- Excessive alcohol consumption (>14 drinks/week for men, >7 drinks/week for women)
- Current tobacco use
- Pregnancy (Premenopausal women will be required to complete a urine pregnancy test before participation)
- History of asthma or chronic obstructive pulmonary disease.
- History of allergic reaction to lactose or milk proteins
- Intranasal live attenuated influenza vaccine (LAIV) given within 2 weeks before zanamivir administration or a planned dose within 48 hours after zanamivir administration. Product insert states to avoid zanamivir administration with intranasal live attenuated influenza vaccine (LAIV).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Zanamivir treatment
Study participants will receive 5 days of treatment with a zanamivir inhaler.
|
5 days of treatment with 10mg zanamivir inhaler BID
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in glycocalyx integrity
Time Frame: 0 and 5 days
|
Measure of glycocalyx integrity via Glycocheck.
Glycocalyx integrity measures will be performed non-invasively.
|
0 and 5 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Vascular function
Time Frame: 0 and 5 days
|
Flow mediated dilation (FMD) in arm.
Brachial artery FMD measures will be performed non-invasively via Ultrasound.
|
0 and 5 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Luis Martinez-Lemus, PhD, University of Missouri, School of Medicine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 14, 2021
Primary Completion (Estimated)
April 13, 2025
Study Completion (Estimated)
April 13, 2025
Study Registration Dates
First Submitted
April 27, 2021
First Submitted That Met QC Criteria
April 27, 2021
First Posted (Actual)
April 30, 2021
Study Record Updates
Last Update Posted (Actual)
July 5, 2023
Last Update Submitted That Met QC Criteria
July 3, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2038203
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Zanamivir
-
GlaxoSmithKlineCompletedInfluenza, Human
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineWithdrawn
-
GlaxoSmithKlineCompletedInfluenza, HumanAustralia, Taiwan, Korea, Republic of, United States, Belgium, Canada, Germany, South Africa, Spain, United Kingdom, New Zealand, Thailand, India, China, Brazil, Hong Kong, Slovakia, Russian Federation, Denmark, Mexico, Czechia, H... and more
-
GlaxoSmithKlineCompletedInfluenza, HumanUnited States, Spain, France, Australia, South Africa, United Kingdom, Thailand, Hong Kong, Canada, Russian Federation, Japan, Norway, Brazil
-
Assistance Publique - Hôpitaux de ParisGlaxoSmithKline; Hoffmann-La RocheTerminated
-
GlaxoSmithKlineCompletedInfluenza, HumanUnited States
-
University of OxfordNational Institute of Allergy and Infectious Diseases (NIAID)Completed